A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

ClinicalTrials.gov ID: NCT06823167

Public ClinicalTrials.gov record NCT06823167. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

Study identification

NCT ID: NCT06823167
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Immunome, Inc.; Industry
Enrollment: 190 participants

Conditions and interventions

Conditions

Interventions

IM-1021 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 25, 2025
Primary completion: Apr 30, 2028
Completion: Jan 31, 2029
Last update posted: Aug 9, 2026

2025 – 2029

United States locations

U.S. sites: 19
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
City Of Hope	Duarte	California	91010	Recruiting
University of California	Los Angeles	California	90095	Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Yale University Medical Center	New Haven	Connecticut	06510	Recruiting
Tampa General Hospital	Tampa	Florida	33606	Recruiting
Emory Winship Cancer Institute	Atlanta	Georgia	30322	Recruiting
University of Iowa	Iowa City	Iowa	52242	Recruiting
Norton Cancer Institute	Louisville	Kentucky	40202	Recruiting
University of Michigan	Ann Arbor	Michigan	48109	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
University of Nebraska Medical Center	Omaha	Nebraska	68105	Recruiting
Levine Cancer Institute	Charlotte	North Carolina	28204	Recruiting
Gabrail Cancer Center	Canton	Ohio	44718	Recruiting
Brown University	Providence	Rhode Island	02903	Recruiting
Sarah Cannon Research Institute - Oncology Partners	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
NEXT Oncology	Irving	Texas	75039	Recruiting
UT San Antonio Mays Cancer	San Antonio	Texas	78229	Recruiting
University of Virginia	Charlottesville	Virginia	22903	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06823167, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 9, 2026 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06823167 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →